Vir Biotechnology, Inc. (VIR)

Vir Biotechnology is a clinical-stage biotech whose bull thesis rests entirely on pipeline execution — particularly its hepatitis B functional cure program and other infectious disease assets that have attracted unanimous Buy ratings across 9 analysts. The consensus price target of $21.56 implies over 100% upside from current levels, reflecting the binary but high-reward nature of its pipeline. The primary risk is that the company is loss-making with a negative forward P/E, burns cash, and has beaten EPS estimates only once in the last four quarters, making near-term financial disappointments a persistent hazard.

• Phase 2/3 hepatitis B program data readouts expected in coming quarters could validate the functional cure thesis and serve as a major re-rating event for the stock.
• Potential partnership or licensing deal for lead pipeline assets could provide non-dilutive capital and validate platform value, as evidenced by strong analyst conviction.
• Any positive Phase 2 interim data from additional infectious disease pipeline programs (e.g., HIV or respiratory viruses) could expand the addressable opportunity and attract new institutional investors.

• Binary clinical risk: a Phase 2/3 failure in the hepatitis B program — the core pipeline asset — could erase the majority of the stock's value given the lack of commercial revenue to support the current price.
• Cash burn risk: with negative earnings and no near-term profitability path (forward P/E of -4.4x), the company may need to raise additional capital, potentially diluting existing shareholders by 20–30% or more.
• Execution risk: an EPS beat rate of only 1 of 4 quarters signals persistent misalignment between management guidance and delivery, raising concerns about forecast reliability and operational discipline.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →